FibroBiologics to Present at the 2025 ThinkEquity Conference
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 2025 ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental, New York City. The company presentation is scheduled for 4:30 p.m. ET on October 30, and management will be available for one-on-one investor meetings throughout the event.
For presentation details or to request a meeting, contact the company via its website or email info@fibrobiologics.com.
Positive
- None.
Negative
- None.
News Market Reaction 4 Alerts
On the day this news was published, FBLG declined 4.20%, reflecting a moderate negative market reaction. Argus tracked a peak move of +16.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $881K from the company's valuation, bringing the market cap to $20M at that time.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City.
FibroBiologics will deliver a company presentation at 4:30 p.m. ET on October 30 and will be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When will FibroBiologics (FBLG) present at the 2025 ThinkEquity Conference?
Who from FibroBiologics (FBLG) will present at the ThinkEquity Conference?
Where is the 2025 ThinkEquity Conference where FibroBiologics (FBLG) will present?
How can investors request a one-on-one meeting with FibroBiologics (FBLG) at the conference?
Will FibroBiologics (FBLG) cover clinical development updates in the October 30 presentation?
Where can I find more information about FibroBiologics (FBLG) presentation logistics for October 30, 2025?
